← All Outlook Therapeutics, INC filings

Outlook Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
OTLK
Outlook Therapeutics, INC
10-K: Outlook Therapeutics Faces Second FDA Rejection for Wet AMD Drug
Outlook Therapeutics received a second Complete Response Letter from the FDA for its wet AMD treatment, ONS-5010/LYTENAVA, citing insufficient evidence of effectiveness, despite recent EU and UK market authorizations.
NASDAQ
OTLK
Outlook Therapeutics, INC
10-K/A: Outlook Therapeutics Files Amendment No. 1 to Form 10-K/A to Include Part III Information
Outlook Therapeutics files an amendment to its Form 10-K to include information required by Part III, which was previously omitted.
NASDAQ
OTLK
Outlook Therapeutics, INC
10-K: Outlook Therapeutics Reports Fiscal Year 2024 Results, Awaits Key Clinical Data for ONS-5010/LYTENAVA
Outlook Therapeutics reports its fiscal year 2024 results, highlighting the European approval of ONS-5010/LYTENAVA and ongoing efforts to secure U.S. approval, while also addressing financial challenges and a recent workforce reduction.
NASDAQ
OTLK
Outlook Therapeutics, INC
10-K/A: Outlook Therapeutics Files Amended 10-K to Include Part III Information
Outlook Therapeutics has filed an amendment to its annual report on Form 10-K to include information previously omitted from Part III of the original filing.